PepGen, Inc. (NASDAQ:PEPG) Stock Has Consensus Price Target of $11.40 According to Brokerages

Shares of PepGen, Inc. (NASDAQ:PEPG) have been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $11.40.

Several research analysts have issued reports on PEPG shares. HC Wainwright reiterated a “buy” rating on shares of PepGen in a report on Wednesday, September 9th. Wall Street Zen cut shares of PepGen from a “hold” rating to a “sell” rating in a research report on Saturday, October 10th. Finally, Weiss Ratings upgraded PepGen from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 22nd.

Hedge Funds Weigh In On PepGen

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Group One Trading LLC acquired a new stake in shares of PepGen during the 1st quarter valued at about $77,000. Seven Fleet Capital Management LP acquired a new stake in shares of PepGen in the 1st quarter valued at approximately $105,000. Rangeley Capital LLC lifted its position in PepGen by 88.1% in the 1st quarter. Rangeley Capital LLC now owns 68,096 shares of the company’s stock valued at $121,000 after acquiring an additional 31,896 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in PepGen in the second quarter valued at approximately $171,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new position in PepGen in the 2nd quarter valued at about $202,000. Institutional investors own 58.01% of the company’s stock.

PepGen Stock Performance

Shares of PEPG stock opened at $2.36 on Friday. PepGen has a 52-week low of $1.31 and a 52-week high of $7.80. The stock has a market cap of $163.45 million, a price-to-earnings ratio of -1.80 and a beta of 2.02. The firm’s 50-day moving average is $2.75 and its 200-day moving average is $3.07.

PepGen (NASDAQ:PEPG) last issued its earnings results on Thursday, August 6th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.28) by $0.02. Sell-side analysts predict that PepGen will post -1.11 EPS for the current fiscal year.

PepGen Company Profile

PepGen Inc is a clinical-stage biotechnology company developing genetic medicines for serious neuromuscular diseases. The company’s technology is designed to improve the delivery of oligonucleotide therapeutics into skeletal and cardiac muscle, with the goal of addressing diseases caused by genetic mutations or abnormal RNA processing.

PepGen’s platform, known as Enhanced Delivery Oligonucleotides (EDO), combines therapeutic oligonucleotides with proprietary peptides intended to facilitate their distribution into muscle tissue.